Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Daiichi Forges Academic Pacts
by Lisa M. Jarvis
May 26, 2014
| A version of this story appeared in
Volume 92, Issue 21
Daiichi Sankyo has inked two deals to tap into academic expertise in early-stage drug discovery. The Japanese firm will work with Sanford-Burnham Medical Research Institute to develop cardiovascular and metabolic disease drugs. Under the three-year pact, the two will identify and validate drug targets; later, each side will conduct screens for molecules that modulate those targets. In a separate deal, Daiichi has partnered with MRC Technology, which handles technology transfer for nonprofits, to identify drug targets that could be developed into oncology, cardiovascular, and metabolic disease treatments.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter